Qsemble Capital Management LP Purchases 119,176 Shares of Pfizer Inc. (NYSE:PFE)

Qsemble Capital Management LP boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 178.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 185,882 shares of the biopharmaceutical company’s stock after buying an additional 119,176 shares during the quarter. Pfizer makes up approximately 1.0% of Qsemble Capital Management LP’s portfolio, making the stock its 11th largest holding. Qsemble Capital Management LP’s holdings in Pfizer were worth $5,379,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of PFE. Acorn Wealth Advisors LLC lifted its holdings in shares of Pfizer by 5.3% in the 3rd quarter. Acorn Wealth Advisors LLC now owns 13,384 shares of the biopharmaceutical company’s stock worth $387,000 after acquiring an additional 679 shares during the last quarter. Private Trust Co. NA lifted its holdings in shares of Pfizer by 1.8% during the third quarter. Private Trust Co. NA now owns 76,205 shares of the biopharmaceutical company’s stock valued at $2,205,000 after purchasing an additional 1,324 shares in the last quarter. Horizon Kinetics Asset Management LLC grew its holdings in shares of Pfizer by 63.3% in the third quarter. Horizon Kinetics Asset Management LLC now owns 93,815 shares of the biopharmaceutical company’s stock worth $2,715,000 after acquiring an additional 36,370 shares during the period. Truvestments Capital LLC lifted its position in Pfizer by 15.3% during the third quarter. Truvestments Capital LLC now owns 14,939 shares of the biopharmaceutical company’s stock valued at $432,000 after purchasing an additional 1,985 shares in the last quarter. Finally, Brown Brothers Harriman & Co. raised its holdings in Pfizer by 3.0% during the third quarter. Brown Brothers Harriman & Co. now owns 210,927 shares of the biopharmaceutical company’s stock valued at $6,104,000 after acquiring an additional 6,232 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Up 1.6 %

PFE stock traded up $0.41 during mid-day trading on Monday, reaching $26.06. The company had a trading volume of 9,010,689 shares, compared to its average volume of 38,360,109. The company has a market capitalization of $147.68 billion, a PE ratio of 34.66, a price-to-earnings-growth ratio of 0.82 and a beta of 0.67. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a 50 day moving average of $28.21 and a 200 day moving average of $28.57.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the company posted ($0.17) EPS. The business’s revenue was up 31.2% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.45%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Barclays increased their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.92.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.